8-K
filed June 5, 2023, 7:59 PM ET
CIK 0001724979
other material
confidence high
sentiment negative
materiality 0.75
Rain Oncology Inc.: restructuring charge — Rain Oncology cuts 65% workforce, suspends Phase 2/1 trials, extends cash runway
Rain Oncology Inc.
- Restructuring plan cuts ~65% of employees; expects $2.4M-$2.6M in charges in Q2 2023.
- Suspends enrollment in Phase 2 MANTRA-2 basket trial; terminates plans for Phase 1/2 MANTRA-4 combo trial.
- Richard Bryce transitions from CMO to advisory role; Robert Doebele named CMO. Joy Bruce becomes principal financial officer.
- Year-end 2023 cash guidance $75-$80M; cash runway extended to year-end 2026.
- Phase 3 MANTRA milademetan data to be presented at a medical conference in 4Q 2023.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 0.95
Joy Bruce changed role as principal financial and accounting officer at Rain Oncology Inc..
- Action
- assumed the role
- Role
- principal financial and accounting officer
Exact text from the filing
Joy Bruce, the Company’s Director of Accounting, assumed the role of the Company’s principal financial and accounting officer, effective as of such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Richard Bryce changed role as Executive Vice President, Chief Medical Officer at Rain Oncology Inc..
- Action
- transitioned from role to advisory position
- Role
- Executive Vice President, Chief Medical Officer
Exact text from the filing
the Company and Dr. Richard Bryce agreed that he would transition from his role as the Company’s Executive Vice President, Chief Medical Officer to an advisory position with the Company, effective June 1, 2023.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Robert Doebele changed role as Chief Medical Officer at Rain Oncology Inc..
- Action
- succeeded as Chief Medical Officer
- Role
- Chief Medical Officer
Exact text from the filing
Dr. Robert Doebele, the Company’s Cofounder, President and Chief Scientific Officer, succeeded Dr. Bryce as the Company’s Chief Medical Officer as of such date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 0.95
Nelson Cabatuan changed role as Senior Vice President, Finance and Operations at Rain Oncology Inc..
- Action
- transitioned from role to advisory position
- Role
- Senior Vice President, Finance and Operations
Exact text from the filing
the Company and Nelson Cabatuan agreed that he would transition from his role as the Company’s Senior Vice President, Finance and Operations to an advisory position with the Company, effective June 1, 2023.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
Rain Oncology Inc. announced a restructuring with charges of approximately $2.4 million to $2.6 million affecting the Company’s current workforce (approximately 65%).
- Type
- restructuring
- Charge
- approximately $2.4 million to $2.6 million
- Affected area
- the Company’s current workforce
- Headcount
- approximately 65%
Exact text from the filing
The Company estimates that it will incur approximately $2.4 million to $2.6 million in charges in connection with the Plan, almost all of which are cash expenditures related to employee transition, severance payments and employee benefits, and less than $0.1 million of which are charges related to non-cash stock-based compensation.
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Rain Oncology Inc. shareholders approved Election of Class II Director Nominees at the 2023-05-31 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
On Wednesday, May 31, 2023, the Company held its 2023 Annual Meeting of Stockholders
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.9
Rain Oncology Inc. shareholders approved Ratification of Ernst & Young LLP as Independent Auditor at the 2023-05-31 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2023-05-31
Exact text from the filing
Proposal 2. Ratification of Ernst & Young LLP as Independent Auditor 22,115,471 6,387 6,453 0
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.